Are we likely to see another sales update for the Chinese market in the very near term?
Notably, the company has restructured and expanded from 10 Chinese distributors to nearly 40, allowing a “more direct pathway” to 10,000 hospitals.
“We will control our entire product delivery pathway,” Professor Phillips says. “We are doubling our margin and doubling our number of distributors.
“Previously we had to sell to a master distributor, who sold to a distributor, then a sub distributor who then sold to a sub sub distributor. Now we have our own system.
“This approach should more than double our margin and it should more than double our volume.”
While Uscom sells mainly to hospitals, it is also targeting the Chinese home market with products such as BP-plus and Spirosonic."
